A randomised controlled trial of low-dose aspirin for the prevention of fractures in healthy older people: protocol for the ASPREE-Fracture substudy
Anna L Barker, John J McNeil, Ego Seeman, Stephanie A Ward, Kerrie M Sanders, Sundeep Khosla, Robert G Cumming, Julie A Pasco, Megan A Bohensky, Peter R Ebeling, Robyn L Woods, Jessica E Lockery, Rory Wolfe, Jason Talevski
INJURY PREVENTION | BMJ PUBLISHING GROUP | Published : 2016
BACKGROUND: Disability, mortality and healthcare burden from fractures in older people is a growing problem worldwide. Observational studies suggest that aspirin may reduce fracture risk. While these studies provide room for optimism, randomised controlled trials are needed. This paper describes the rationale and design of the ASPirin in Reducing Events in the Elderly (ASPREE)-Fracture substudy, which aims to determine whether daily low-dose aspirin decreases fracture risk in healthy older people. METHODS: ASPREE is a double-blind, randomised, placebo-controlled primary prevention trial designed to assess whether daily active treatment using low-dose aspirin extends the duration of disabilit..View full abstract
Awarded by Australian National Health and Medical Research Council (NHMRC) Project Grant
Awarded by NHMRC Career Development Fellowship
Awarded by NATIONAL INSTITUTE ON AGING
This project is funded by an Australian National Health and Medical Research Council (NHMRC) Project Grant (APP1067242). ALB is supported by a NHMRC Career Development Fellowship (APP1067236). Bayer Pharma AG provides blinded aspirin and placebo.